Loading
Every phase 2 or 3 interventional trial that was recruiting, about to open or still running for pancreatic cancer on ClinicalTrials.gov in September 2026, with the hospitals in the United Kingdom that take part named where the registry lists them.
The ClinicalTrials.gov v2 API was searched on 24 September 2026 for interventional phase 2, 1/2, 2/3 and 3 studies naming pancreatic cancer that were recruiting, not yet recruiting, enrolling by invitation or (for phase 3 and 2/3) active but closed: 589 studies, of which 209 were already in the corpus, 36 were neuroendocrine-only and are left out, and 284 are carried as registry-only records linked here (163 phase 2, 72 phase 1/2, 33 phase 3 and 16 phase 2/3; 183 recruiting, 97 not yet recruiting, 4 phase 3 or 2/3 trials active but closed). Most are run from the United States (120 of the new trials) and China (119), then France, Canada, Spain, the Netherlands, South Korea, Australia, the United Kingdom and Italy. The phase 3 questions open today are perioperative against adjuvant chemotherapy for resectable disease (Alliance A021806, PREOPANC-3, NeoFOL-R, LEFT-PANC), prolonged neoadjuvant chemotherapy for borderline and locally advanced disease (ADVANTAGE), dose-escalated radiotherapy for locally advanced disease (LAP100), adjuvant chemoradiotherapy (ADJUPANC), switch maintenance (PANThEON), first-line RAS inhibition (RASolute 303, RASolute 305, RASolute 309, DAWN-303), adjuvant daraxonrasib (RASolute 304), quemliclustat (PRISM-1) and claudin 18.2 antibodies. UK hospitals appear in RASolute 303 (Torbay, Birmingham, Cambridge, Barts, the Royal Marsden, the Christie), RASolute 304 (Birmingham, Glasgow, Liverpool, the Royal Marsden, Hammersmith, the Christie), IMCODE003 (eight sites), PRISM-1, DAWN-303 (nine sites), the setidegrasib trial NCT07409272 (seven sites), the pembrolizumab and olaparib trial NCT05093231 (15 sites, led from Cambridge), STARPAC2 (Barts) and the DETERMINE platform. The ISRCTN registry lists 176 hits for pancreatic cancer, 97 naming the disease, most of them UK surgical, diagnostic and observational studies; the interventional UK trials with results (SCALOP, ESPAC-4, ESPAC-5, SIEGE) and the open ones (STARPAC2, PRIMUS 001, DETERMINE) are hand-written.
Shares Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes, Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer, Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer, Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer.
Shares Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001), Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer, Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients, Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer.
Shares Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients, Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer, Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer, Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes.
Shares A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer, Central-boost Ablative Radiation Therapy for Solid Tumors (CBART), Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers, Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic.
Shares Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001), Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP, A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca, Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer.
Shares Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan, A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers, IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer, Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab.
Shares Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer, NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer, Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab, Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV.
Shares NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer), mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients, Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer, 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC.